Novo Nordisk’s SOUL trial confirms that oral semaglutide significantly reduces the risk of heart attack, stroke, and ...

Building on results of the landmark SELECT trial, SCORE shows cardiovascular (CV) risk reduction with use of semaglutide 2.4 mg in a real-world environment 1 SCORE is a retrospective ...

A “game-changing” Ozempic-style daily pill could transform public health in Britain, experts have said. The drug is expected ...

HANOI, VIETNAM – Media OutReach Neswire – 14 April 2025 – Together with world-renowned scientists including Prof. Joel F.

HANOI, VIETNAM - Media OutReach Neswire - 14 April 2025 - Together with world-renowned scientists including Prof. Joel F.

Beyond diabetes 2024 was a landmark year for GLP-1 research ... He elaborated, "We have trials underway for Alzheimer's disease with oral semaglutide, which are expected to conclude by the end of 2025 ...

Explore how innovation, R&D, and policy reforms are reshaping China’s pharmaceutical sector amid rising healthcare demand and ...